Literature DB >> 19840674

Influenza virus CTL epitopes, remarkably conserved and remarkably variable.

Guus F Rimmelzwaan1, Joost H C M Kreijtz, Rogier Bodewes, Ron A M Fouchier, Albert D M E Osterhaus.   

Abstract

Virus-specific cytotoxic T lymphocytes (CTL) contribute to the control of virus infections including those caused by influenza viruses. Especially under circumstances when antibodies induced by previous infection or vaccination fail to recognize and neutralize the virus adequately, CTL are important and contribute to protective immunity. During epidemic outbreaks caused by antigenic drift variants and during pandemic outbreaks of influenza, humoral immunity against influenza viruses is inadequate. Under these circumstances, pre-existing CTL directed to the relatively conserved internal proteins of the virus may provide cross-protective immunity. Indeed, most of the known human influenza virus CTL epitopes are conserved. However, during the evolution of influenza A/H3N2 viruses, the most important cause of seasonal influenza outbreaks, variation in CTL epitopes has been observed. The observed amino acid substitutions affected recognition by virus-specific CTL and the human virus-specific CTL response in vitro. Examples of variable epitopes and their HLA restrictions are: NP(383-391)/HLA-B*2705, NP(380-388)/HLA-B*0801, NP(418-426)/HLA-B*3501, NP(251-259)/HLA-B*4002, NP(103-111)/HLA-B*1503. In some cases amino acid substitutions occurred at anchor residues and in other cases at T cell receptor contact residues. It is of special interest that the R384G substitution in the NP(383-391) epitope was detrimental to virus fitness and was only tolerated in the presence of multiple functionally compensating co-mutations. In contrast, other epitopes, like the HLA-A*0201 restricted epitope from the matrix protein, M1(58-66), are highly conserved despite their immunodominant nature and the high prevalence of HLA-A*0201 in the population. A mutational analysis of this epitope indicated that it is under functional constraints. Also in influenza A viruses of other subtypes, including H5N1, the M1(58-66) is highly conserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19840674     DOI: 10.1016/j.vaccine.2009.01.016

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  37 in total

1.  Positive Selection in CD8+ T-Cell Epitopes of Influenza Virus Nucleoprotein Revealed by a Comparative Analysis of Human and Swine Viral Lineages.

Authors:  Heather M Machkovech; Trevor Bedford; Marc A Suchard; Jesse D Bloom
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

2.  Annual vaccination against influenza virus hampers development of virus-specific CD8⁺ T cell immunity in children.

Authors:  Rogier Bodewes; Pieter L A Fraaij; Martina M Geelhoed-Mieras; Carel A van Baalen; Harm A W M Tiddens; Annemarie M C van Rossum; Fiona R van der Klis; Ron A M Fouchier; Albert D M E Osterhaus; Guus F Rimmelzwaan
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

Review 3.  Cell culture-based influenza vaccines: A necessary and indispensable investment for the future.

Authors:  Nagendra R Hegde
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Engineering temperature sensitive live attenuated influenza vaccines from emerging viruses.

Authors:  Bin Zhou; Yan Li; Scott D Speer; Anju Subba; Xudong Lin; David E Wentworth
Journal:  Vaccine       Date:  2012-03-24       Impact factor: 3.641

5.  Systematic identification of immunodominant CD8+ T-cell responses to influenza A virus in HLA-A2 individuals.

Authors:  Chao Wu; Damien Zanker; Sophie Valkenburg; Bee Tan; Katherine Kedzierska; Quan Ming Zou; Peter C Doherty; Weisan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-11       Impact factor: 11.205

Review 6.  Evasion of innate and adaptive immune responses by influenza A virus.

Authors:  Mirco Schmolke; Adolfo García-Sastre
Journal:  Cell Microbiol       Date:  2010-05-06       Impact factor: 3.715

7.  Comparative studies of infectivity, immunogenicity and cross-protective efficacy of live attenuated influenza vaccines containing nucleoprotein from cold-adapted or wild-type influenza virus in a mouse model.

Authors:  Irina Isakova-Sivak; Daniil Korenkov; Tatiana Smolonogina; Tatiana Tretiak; Svetlana Donina; Andrey Rekstin; Anatoly Naykhin; Svetlana Shcherbik; Nicholas Pearce; Li-Mei Chen; Tatiana Bousse; Larisa Rudenko
Journal:  Virology       Date:  2016-11-06       Impact factor: 3.616

8.  The impact of matching vaccine strains and post-SARS public health efforts on reducing influenza-associated mortality among the elderly.

Authors:  Ta-Chien Chan; Chuhsing Kate Hsiao; Chang-Chun Lee; Po-Huang Chiang; Chuan-Liang Kao; Chung-Ming Liu; Chwan-Chuen King
Journal:  PLoS One       Date:  2010-06-25       Impact factor: 3.240

9.  Controlling influenza by cytotoxic T-cells: calling for help from destroyers.

Authors:  Michael Schotsaert; Lorena Itatí Ibañez; Walter Fiers; Xavier Saelens
Journal:  J Biomed Biotechnol       Date:  2010-05-24

10.  Conservation and diversity of influenza A H1N1 HLA-restricted T cell epitope candidates for epitope-based vaccines.

Authors:  Paul Thiamjoo Tan; A T Heiny; Olivo Miotto; Jerome Salmon; Ernesto T A Marques; Francois Lemonnier; J Thomas August
Journal:  PLoS One       Date:  2010-01-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.